Clinical trial
A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer
NCT00193323 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- SCRI Development Innovations, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2001
- Completion date
- January 31, 2009
- Enrollment
- 346
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer